Document Detail


Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients.
MedLine Citation:
PMID:  18570597     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: The management of obese hypertensive subjects may require the administration of anti-obesity and antihypertensive drugs. Sibutramine use has raised concerns regarding a potential increase in subjects' blood pressure and heart rate. The primary end-points of this study were an evaluation of the effect of sibutramine together with a verapamil sustained release/trandolapril combination tablet versus verapamil sustained release/trandolapril alone on the blood pressure and heart rate in obese hypertensive patients. RESEARCH DESIGN/METHODS: Patients received a low-fat low-calorie diet and were randomly allocated to open-label verapamil sustained release/trandolapril 180/2 mg (n = 26) or sibutramine 10 mg together with verapamil sustained release/trandolapril 180/2 mg (n = 28) daily for 6 months. RESULTS: Significant reductions in the subjects' systolic blood pressure and diastolic blood pressure were observed in both groups (p < 0.01 versus baseline). At 6 months a greater fall in blood pressure was observed in the sibutramine/verapamil sustained release/trandolapril group compared with the verapamil sustained release/trandolapril group (systolic blood pressure 21.9 +/- 8.1 versus 15.9 +/- 12.3 mmHg and diastolic blood pressure 15.7 +/- 8.1 versus 9.1 +/- 9.9 mmHg) but this was only significant (p = 0.03) for diastolic blood pressure. The subjects' heart rate did not change significantly in any group. No significant sibutramine-associated attenuation of blood pressure reduction was observed during the study. The sibutramine/verapamil sustained release/trandolapril treatment resulted in significantly greater improvement in the subjects' anthropometric variables, homeostasis model assessment and lipid profiles compared with verapamil sustained release/trandolapril administration. The subjects' small dense low-density lipoprotein cholesterol, high-sensitivity C-reactive protein and visfatin plasma levels were only measured in the sibutramine/verapamil sustained release/trandolapril group (all decreased by p < 0.05 versus baseline). CONCLUSIONS: The sibutramine/verapamil sustained release/trandolapril combination in obese hypertensive patients significantly reduced their blood pressure and improved their anthropometric and metabolic variables without affecting the heart rate.
Authors:
E Nakou; T D Filippatos; E N Liberopoulos; A D Tselepis; D N Kiortsis; D P Mikhailidis; M S Elisaf
Related Documents :
14575277 - Effects of manidipine and nifedipine on blood pressure and renal function in patients w...
6599697 - Pressor factors and cardiovascular pressor responsiveness after short-term antihyperten...
3767537 - Management of perioperative hypertension using sublingual nifedipine. experience in eld...
2864857 - Nifedipine in combination therapy for chronic hypertension. a review.
1410177 - Respiratory sinus arrhythmia and cardiovascular responses to stress.
20481727 - Glassy dynamics under superhigh pressure.
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  9     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2008 Jul 
Date Detail:
Created Date:  2008-06-23     Completed Date:  2008-08-11     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  1629-39     Citation Subset:  IM    
Affiliation:
University of Ioannina, Department of Internal Medicine, School of Medicine, 45 110 Ioannina, Greece. egepi@cc.uoi.gr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antihypertensive Agents / administration & dosage,  therapeutic use*
Appetite Depressants / administration & dosage,  therapeutic use*
Blood Pressure / drug effects
Body Weights and Measures
C-Reactive Protein / analysis
Cyclobutanes / administration & dosage,  therapeutic use*
Delayed-Action Preparations
Diet
Drug Combinations
Drug Therapy, Combination
Female
Heart Rate / drug effects
Humans
Hypertension / complications,  drug therapy*
Indoles / administration & dosage,  therapeutic use*
Lipids / blood
Male
Nicotinamide Phosphoribosyltransferase / drug effects
Obesity / complications,  drug therapy*
Verapamil / administration & dosage,  therapeutic use*
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Appetite Depressants; 0/Cyclobutanes; 0/Delayed-Action Preparations; 0/Drug Combinations; 0/Indoles; 0/Lipids; 106650-56-0/sibutramine; 52-53-9/Verapamil; 87679-37-6/trandolapril; 9007-41-4/C-Reactive Protein; EC 2.4.2.12/Nicotinamide Phosphoribosyltransferase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Socioeconomic inequalities of tuberculosis in India.
Next Document:  Quality of life in hypertension management using olmesartan in primary care.